Related Experiment Video

Updated: May 13, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Selective blockade of transport via SERCA inhibition: the answer for oncogenic forms of Notch?

Ma Xenia G Ilagan1, Raphael Kopan

  • 1Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA. ilaganmg@wustl.edu

Cancer Cell
|March 23, 2013
PubMed

Insights

Targeting SERCA calcium pumps may treat T cell acute lymphoblastic leukemia. Inhibiting these pumps impairs the maturation of common oncogenic Notch1 mutants, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Calcium Signaling

Background:

  • NOTCH1 mutations are common in T cell acute lymphoblastic leukemia (TALL), presenting a significant therapeutic challenge.
  • Identifying effective therapeutic targets for TALL driven by NOTCH1 alterations is crucial.

Discussion:

  • Roti and colleagues identified SERCA calcium pumps as a potential therapeutic target.
  • Inhibition of SERCA calcium pumps selectively affects the maturation of prevalent oncogenic Notch1 mutants.

Key Insights:

  • SERCA calcium pump inhibition demonstrates preferential impact on common NOTCH1 oncogenic mutants.
  • This finding opens a potential therapeutic avenue for TALL patients with specific NOTCH1 mutations.

Outlook:

  • Further research into SERCA calcium pump inhibitors could lead to novel TALL treatments.
  • This study highlights the importance of targeting calcium signaling pathways in TALL therapy.

More Related Videos

Stimulation of Notch Signaling in Mouse Osteoclast Precursors08:01

Stimulation of Notch Signaling in Mouse Osteoclast Precursors

Published on: February 28, 2017

Related Concept Videos

Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...